日本語 
Australian diagnostics innovator Q, Sera Pty Ltd has announced that its patented RAPClot blood, collection technology has been commercially launched for the first time in Japan through a partnership with Terumo Corporation. The product—introduced as the VenoJect II RAPClot tube—represents the company’s initial step toward global commercialization of its rapid serum-generation platform.
The launch makes Japan the first country to use the next, generation tubes and it is expected to lead to further international partnerships in diagnostic and healthcare ecosystems.
How RAPClot Technology Improves Laboratory Workflows
RAPClot technology uses recombinant ecarin, a protein derived from prothrombin activators originally identified in snake venom, to accelerate blood clotting in collection tubes. Laboratories are now able to produce high, quality serum samples at a much quicker pace than when they were using regular tubes, thanks to this method.
Also Read: Eisai and Henlius Sign Japan Rights Deal for Serplulimab
When researchers utilize these tubes, they can expect to achieve usable serum in approximately five minutes, even if their samples have anticoagulants. This is a great help to clinicians because it means that the time from obtaining the sample to performing biochemical analysis is now shorter. With quicker turnaround times, diagnostic accuracy can be improved, laboratory operations can be made more efficient, and patient management can benefit from the support of time, critical care scenarios.
Exclusive Japanese Partnership With Terumo
According to the contract, Terumo is the only one who has the right to make and sell RAPClot, enabled tubes in the Japanese market. The implementation of the production expansion program to introduce the recombinant protein into commercially scaled biopharmaceutical processes was the most important part of the release. This ensured a consistent quality level for the healthcare sector.
Top leaders of the two companies consider the launch among the groundbreaking changes of the last 20, 30 years in a product category that has been seeing very little innovation. By solving problems of slow coagulation, difficulties with heparinized blood, and fibrin noise in tests, the new product is expected to not only increase the accuracy of diagnostics but also to make the laboratory work more efficient.
Strategic Importance for the Global Diagnostics Market
The blood-collection tube segment is foundational to modern diagnostics, supporting everything from emergency testing to chronic disease monitoring. Improvements in sample preparation can have a cascading impact on:
Clinical decision speed
Laboratory throughput and automation
Healthcare system cost efficiency
Patient outcomes and treatment timelines
Because serum quality directly affects analytical accuracy, technologies that reduce pre-analytical delays or variability can deliver significant operational benefits for hospitals and pathology networks.
Expansion Plans Beyond Japan
Q-Sera said that the Japanese launch is just the first phase of its commercialization roadmap. The company is therefore opening talks on further licensing and distribution agreements that would allow the RAPClot technology to be introduced in other regional diagnostic markets.
The know, how for the system is made up of research work at The University of Queensland that was commercialized with the help of UniQuest and through investments from life, science venture funds.
Industry Outlook: Faster Diagnostics as a Healthcare Priority
Healthcare systems all over the world are under a great deal of pressure to diagnose their cases faster without losing the accuracy that means innovations in pre, analytical processes like quick serum production are attracting more and more attention.
One example of such innovation is the introduction of RAPClot, based tubes, which shows how small improvements in routine medical supplies may bring significant efficiency gains, especially in emergency care, high, volume laboratories, and automated testing environments.
Should the whole world follow Japan’s lead, we may witness a revolutionary change in biochemical sample preparation standards and laboratory productivity, all thanks to rapid, clotting collection technologies.
English